Clinical Trial

Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction

Study acronym: CLN-0154
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 12, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-12.
Trial Details
NCT Number NCT07415330
Lead Sponsor Demaod Ltd
Conditions Dry Eye, Dry Eye Syndromes
Enrollment 20 participants
Start Date 2026-07-20
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-12